Across TCGA pan-cancer cohorts, ALYREF mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ALYREF data layer compared with 29 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ALYREF mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ALYREF expression acts as an unfavorable survival marker, although some lineages such as COAD and LSCC show a favorable association.

HNSC, PDAC, and COAD are the cancer types where ALYREF mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.234	0.895	<.001	68	view →
PDAC	DFS	Tertile	III,IV	0.213	0.636	.002	26	view →
COAD	DFS	Median	All	1.000	0.892	.028	12	view →
LSCC	DFS	Quartile	II,III,IV	0.868	0.476	.027	2	view →
CCRCC	OS	Tertile	All	0.934	1.000	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ALYREF tumor-vs-normal RNA expression · all ALYREF data types